Ad Header



The Pulse of the Pharmaceutical Industry

  • Filter By Category

  • Filter By Author

NJ ice cream shop teams up with ALS Ice Bucket Challenge co-founder

Seven Scoops ice cream shop in Pine Brook, New Jersey, is donating every penny of ice cream sales on Aug. 26th to support ALS Ice Bucket Challenge Co-Founder Pat Quinn.

Read More »

Biohaven’s ALS treatment fails to win FDA nod

Biohaven Pharmaceutical Holding Co. Ltd. said the U.S. health regulator failed to approve the company’s treatment for amyotrophic lateral sclerosis, or Lou Gehrig’s disease.

Read More »

Cytokinetics’ ALS Treatment Fails to Hit Endpoints in Phase II, Company Notes Several Positive Results

Shares of Cytokinetics Inc. were down more than 15 percent after the company announced that the experimental amyotrophic lateral sclerosis treatment reldesemtiv failed to hit endpoints in a Phase II trial.

Read More »

QurAlis Spins out Med Device Company EnClear to Target ALS

EnClear Therapies – a new medical device company spun out from QurAlis – will focus developmental programs on targeting neurological diseases, including amyotrophic lateral sclerosis and progressive supranuclear palsy.

Read More »

AI Company Verge Genomics Snags $32 Million in Series A Funding

Verge Genomics, a drug discovery company that uses artificial intelligence and machine learning to develop new therapeutics, secured $32 million in a Series A financing round to accelerate its drug discovery programs.

Read More »

Flex Pharma Shutters Phase II ALS Program

Boston-based Flex Pharma announced the closing of a Phase II clinical trial of FLX-787 in amyotrophic lateral sclerosis (ALS) and Charcot-Marie-Tooth (CMT).

Read More »

Wave Life Sciences and Takeda Form Global Strategic Collaboration to Advance Therapies for Central Nervous System Disorders

Wave Life Sciences Ltd. announced the formation of a global strategic collaboration with Takeda Pharmaceutical Company Ltd. to discover, develop and commercialize nucleic acid therapies for disorders of the central nervous system.

Read More »

Ad Right Top


Extensive pharmaceutical business and marketing intelligence. For back issues, please contact

October 2019 Focus: Top 50 Company Profiles & Financials, Outcomes Creativity Index, and more!


Ad Right Bottom